David A. Siegel Dyne Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 76,100 shares of DYN stock, worth $937,552. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,100
Previous 60,700
25.37%
Holding current value
$937,552
Previous $2.18 Million
17.8%
% of portfolio
0.0%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$98.8 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$91 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$90.9 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$82.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$78.6 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $638M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...